Diligence report Multi-omics AI, precision health, biomarker discovery, and clinical diagnostics support Late-stage private unicorn with stale public valuation signal

iCarbonX

iCarbonX Public-Source Startup Diligence Report

The diligence case depends on whether iCarbonX can convert public product/market credibility in Multi-omics AI, precision health, biomarker discovery, and clinical diagnostics support into durable revenue, defensible economics, and compliant operations at or above the $1B public valuation signal.

Company profile

iCarbonX Public-Source Startup Diligence Report

iCarbonX is eligible for this run as an uncovered private unicorn based on CB Insights and active public-source evidence, but public diligence is gap-heavy because financial, customer, legal, and personnel records are private.

Website: www.icarbonx.com
Sector: Multi-omics AI, precision health, biomarker discovery, and clinical diagnostics support
Geography: China; Shenzhen, Guangdong Province
Stage: Late-stage private unicorn with stale public valuation signal
Known aliases: iCarbonX Research, Tan Yun Intelligence
Report version: 1.0
Timezone: UTC

Executive summary

Strengths

CB Insights lists iCarbonX as a private unicorn valued at $1B, with a 2016-04-12 unicorn date, Shenzhen location, healthcare industry classification, and named select investors Tencent and Vcanbio.
iCarbonX says it was founded in 2015 by Jun Wang to create a future where people can drive health and defeat disease with advanced data and AI.
Company-owned investor disclosures list Tencent, VCANBIO Life Sciences, and UEC Group as investors/partners supporting the company.
iCarbonX says its Digital Life Platform integrates genomics, proteomics, metabolomics, microbiome, and phenotypical profiling and shifted focus in 2019 toward innovative biomarker discoveries for translational work.

Risks

Stale valuation and thin recent commercial evidence
Health/genomics data and diagnostics regulatory exposure
Clinical validation and proprietary dataset defensibility gaps

Gaps

Audited financial statements, monthly management accounts, revenue bridge, gross margin, cash runway, debt, tax, and AR aging are not public.
Fully diluted cap table, liquidation preferences, investor rights, options, warrants, and notes are not public.
Named customers, contract values, churn, NRR/GRR, revenue concentration, and referenceability require private schedules.
Current headcount, org chart, turnover, compensation, and incentive-equity details are not sufficiently public.
Legal, regulatory, IP, privacy, security, insurance, and material-contract schedules need counsel and management confirmation.

Recommended next steps

Provide audited financial statements, monthly financial model, ARR/GMV/revenue bridge, gross margin, cash runway, debt, and tax schedules.
Provide cap table, financing documents, investor rights, option/warrant/note schedules, litigation schedule, regulatory correspondence, material contracts, and IP assignment records.
Provide top customers, contract terms, churn, renewal rates, pipeline, sales productivity, customer references, and partner/supplier concentration.
Provide current org chart, headcount by function/location, compensation philosophy, incentive plans, turnover, employee-relations matters, and key-person retention plans.
Provide product roadmap, architecture, security audits, privacy assessments, compliance policies, incident history, and product-level P&L.

Risk register

high high likelihood

R-001: Stale unicorn valuation and financial quality gap

The $1B valuation signal dates to 2016 and no current audited financials, revenue, cash runway, or cap table are public.

Diligence request: Request audited statements, revenue by product, cash runway, cap table, debt, and latest third-party valuation marks.

high medium likelihood

R-002: Thin recent commercial traction evidence

Public English news is concentrated around 2015-2018 milestones, while current customer contracts, renewals, and product revenue are not public.

Diligence request: Request current customer list, contract values, pipeline, churn, and evidence of active products/partnerships.

high medium likelihood

R-003: Health/genomics data and diagnostics regulatory exposure

Digital health, multi-omics data, clinical cohorts, EUA diagnostics, and cross-border data issues create material regulatory and privacy diligence needs.

Diligence request: Request regulatory correspondence, ethics approvals, consent forms, cybersecurity/privacy audits, and clinical quality-system records.

high medium likelihood

R-004: Clinical validation and performance-claim risk

Biomarker and diagnostic performance claims require independent validation cohorts, protocols, and regulatory review beyond company pages.

Diligence request: Request study protocols, validation data, publications, regulatory submissions, and customer reference calls.

medium medium likelihood

R-005: Key-person and founder concentration risk

Public leadership centers on Jun Wang, Yingrui Li, and Hao Li; current management depth and retention are not public.

Diligence request: Request org chart, leadership employment status, succession plan, retention packages, and turnover.

medium unknown likelihood

R-006: Strategic investor and partnership dependency

Tencent, VCANBIO, UEC, and historical ecosystem partners are public, but current commitments, exclusivity, data rights, and governance terms are not.

Diligence request: Request investor rights, partnership agreements, data-rights schedules, exclusivity clauses, and related-party transaction details.

Chapter 01

01Financial Information

Public research confirms a $1B unicorn valuation signal and named strategic investors, but the valuation is old and no current financial statements, revenue, cap table, debt, or runway data are public.

EC-001 EC-003 EC-009

I.A Annual and quarterly financial information for the past three years

not publicly verifiable confidence: low

Public sources provide structured evidence for annual and quarterly financial information for the past three years, but private records remain required for complete diligence.

EC-001

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section I.A.

Public revenue, unit-economic, and forecast signals
metric or signal	public evidence	verification status	financial inference	diligence request
Audited revenue and EBITDA	Not disclosed in reviewed public sources	not_publicly_verifiable	Cannot validate revenue scale or quality from public data.	Audited financial statements, monthly trial balance, revenue recognition memo.
Product/pricing signals	Digital Life Platform services: No public price list or contract value found; SARS-CoV-2 NP Ab ELISA kit: No public unit price, margin, or sales history found in fetched source set; Meum / consumer health platform: No current public pricing or active consumer adoption data found	partially_verified	Shows monetization surface but not realized ARR/GMV/margins.	Product-level P&L, cohort revenue, gross margin, CAC, payback.
Backlog / customer concentration	Not disclosed in reviewed public sources	not_publicly_verifiable	Revenue predictability and concentration risk remain unresolved.	Bookings, backlog, deferred revenue, top customer schedule, AR aging.

I.B Financial Projections

not publicly verifiable confidence: low

Public sources provide limited direct evidence for financial projections; this section is primarily a diligence-request ledger.

EC-001

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section I.B.

I.C Capital Structure

not publicly verifiable confidence: low

Public sources provide structured evidence for capital structure, but private records remain required for complete diligence.

EC-001

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section I.C.

Capital structure and ownership diligence snapshot
stakeholder	public position	known public signal	verification status	diligence request
iCarbonX	Late-stage private unicorn with stale public valuation signal	$1B public unicorn valuation	verified public database signal	Provide fully diluted cap table, share classes, preferences, and option pool.
Tencent	Select investor named publicly	Named in CB Insights or company investor materials	verified / partially_verified	Confirm ownership percentage, board rights, side letters, and related-party obligations.
Vcanbio	Select investor named publicly	Named in CB Insights or company investor materials	verified / partially_verified	Confirm ownership percentage, board rights, side letters, and related-party obligations.

I.D Other financial information

partially verified confidence: medium

Public sources provide structured evidence for other financial information, but private records remain required for complete diligence.

EC-001

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section I.D.

Public funding and unicorn valuation history
date	event	amount or valuation	investors or counterparties	verification status	diligence caveat
2016-04-12	CB Insights unicorn-list valuation signal	$1B	Tencent; Vcanbio	verified public database signal	Need financing documents, cap table, liquidation preferences, and latest fair-value marks.
Current public-source review	No IPO/acquisition/shutdown evidence found in reviewed public sources	Not applicable	Active company/public pages and unicorn-list row	partially_verified	Confirm legal status, good standing, and current ownership through registry and counsel.

Funding and valuation timeline Public financing/valuation milestones and private-data gaps.

Public valuation trajectory Chart public valuation anchors and missing private marks.

Chapter 02

02Products

iCarbonX publicly describes a multi-omics Digital Life Platform, biomarker discovery services, and a SARS-CoV-2 antibody ELISA product; commercial adoption and pricing remain opaque.

EC-002 EC-005 EC-008

II.A Description of each product

partially verified confidence: medium

Public sources provide structured evidence for description of each product, but private records remain required for complete diligence.

EC-001 EC-002 EC-004 EC-005 EC-006

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section II.A.

Product and service matrix
product or service	target audience	public description	evidence claim id	verification status
Digital Life Platform	Clinical researchers, doctors, translational partners	Multi-omics platform integrating genomics, proteomics, metabolomics, microbiome, and phenotypical profiling	EC-005	verified
Biomarker discovery services	Research hospitals and translational partners	Cancer, chronic disorder, and infectious disease biomarker discovery support	EC-005	verified
SARS-CoV-2 NP Ab ELISA kit	Clinical laboratories	Qualitative detection of total antibodies against SARS-CoV-2 NP under EUA context	EC-006	partially_verified
Meum platform / Digital Life Alliance	Consumer/health ecosystem partners	Historical 2017 platform/alliance launch; current status not clear	EC-004	partially_verified

Pricing and commercialization signals
offering	pricing model	public signal	evidence claim id	verification status
Digital Life Platform services	B2B research / clinical partners	No public price list or contract value found	EC-009	not_publicly_verifiable
SARS-CoV-2 NP Ab ELISA kit	Clinical labs	No public unit price, margin, or sales history found in fetched source set	EC-006	not_publicly_verifiable
Meum / consumer health platform	Historical consumer/digital health users	No current public pricing or active consumer adoption data found	EC-004	inconclusive

Product and dependency architecture Public product architecture inferred from company pages.

Chapter 03

03Customer Information

Public customer evidence is concentrated in historical partnerships, investor ecosystem references, and broad collaboration claims rather than current contract lists or customer revenue.

EC-004

III.A Top customers by application

partially verified confidence: medium

Public sources provide structured evidence for top customers by application, but private records remain required for complete diligence.

EC-001 EC-002 EC-004 EC-005 EC-006 EC-003

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section III.A.

Publicly known customers, users, and applications
customer or segment	application	public evidence	evidence claim id	verification status
Leading health research institutions and providers	Digital Life Platform collaborations	Company says it collaborates with leading institutions/providers; named customers and revenue not public	EC-005	partially_verified
HealthTell / China, Singapore, Taiwan immune profiling	Strategic partnership	Company news lists HealthTell partnership	EC-004	partially_verified
PatientsLikeMe / Digital Life Alliance	Historical ecosystem partnership	Wikipedia and company news describe Digital Life Alliance and PatientsLikeMe partnership/investment	EC-004	partially_verified

III.B Strategic relationships

partially verified confidence: medium

Public sources provide structured evidence for strategic relationships, but private records remain required for complete diligence.

EC-001 EC-002 EC-004 EC-005 EC-006 EC-003

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section III.B.

Strategic relationships and partnerships
partner	relationship type	public evidence or gap	evidence claim id	verification status
Tencent	Strategic investor	Company-owned investor page and CB row identify Tencent	EC-003	verified
VCANBIO Life Sciences	Strategic investor / biotech ecosystem	Company-owned investor page and CB row identify Vcanbio	EC-003	verified
UEC Group	Investor / digital infrastructure ecosystem	Company-owned investor page identifies UEC Group	EC-003	verified
HealthTell / HealthLoop / BUSPH / OP Financial / DaChan Food	Historical collaborations and investments	Company news lists partnerships and investments; current status private	EC-004	partially_verified

Customer and partner concentration proxy Show disclosed public customer/partner anchors and undisclosed concentration gaps.

III.C Revenue by customer

not publicly verifiable confidence: low

Public sources provide limited direct evidence for revenue by customer; this section is primarily a diligence-request ledger.

EC-001 EC-002 EC-004 EC-005 EC-006 EC-003

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section III.C.

III.D Significant relationships severed within the last two years

not publicly verifiable confidence: low

Public sources provide limited direct evidence for significant relationships severed within the last two years; this section is primarily a diligence-request ledger.

EC-001 EC-002 EC-004 EC-005 EC-006 EC-003

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section III.D.

III.E Top suppliers

partially verified confidence: medium

Public sources provide structured evidence for top suppliers, but private records remain required for complete diligence.

EC-001 EC-002 EC-004 EC-005 EC-006 EC-003

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section III.E.

Supplier and infrastructure dependency snapshot
supplier or dependency	role	public evidence	evidence claim id	verification status	diligence request
Sequencing / omics assay infrastructure	Core platform inputs	Vendor names, capacity, cost, and quality agreements not public	EC-005	not_publicly_verifiable	Request private source documents, management schedules, and third-party confirmations.
Clinical samples / hospital research cohorts	Biomarker discovery data input	Company cites research hospitals and cohorts but does not disclose contracts or data rights	EC-011	not_publicly_verifiable	Request private source documents, management schedules, and third-party confirmations.
Regulated diagnostic manufacturing / QA	ELISA kit production and compliance	EUA context visible; quality-system records and suppliers private	EC-006	not_publicly_verifiable	Request private source documents, management schedules, and third-party confirmations.

Chapter 04

04Competition

Competition spans precision medicine data platforms, diagnostic developers, sequencing/omics providers, and internal hospital/research platforms; differentiation requires clinical validation and proprietary data proof.

IV.A Competitive landscape by market segment

partially verified confidence: medium

Public sources provide structured evidence for competitive landscape by market segment, but private records remain required for complete diligence.

EC-001 EC-002 EC-004 EC-005

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section IV.A.

Competitor comparison matrix
competitor	segment	product overlap	differentiator to test	evidence claim id
Tempus AI / precision medicine platforms	AI/omics clinical data platforms	Competes for oncology data, biomarker, and clinical partnership workflows	Request win/loss, price benchmarking, retention, and customer-reference evidence.	EC-005
BGI-linked precision health ecosystem	Genomics and sequencing services	Founders came from BGI; iCarbonX must prove differentiated commercial focus	Request win/loss, price benchmarking, retention, and customer-reference evidence.	EC-007
Guardant Health / Freenome / Grail-type diagnostics	Cancer screening and biomarker tests	Compete around clinical validation and regulatory pathways	Request win/loss, price benchmarking, retention, and customer-reference evidence.	EC-011
Hospital/research-institute internal omics platforms	In-house R&D alternatives	Compete for translational biomarker budgets and data access	Request win/loss, price benchmarking, retention, and customer-reference evidence.	EC-005

Basis-of-competition scoring
axis	target public position	evidence strength	hidden risk	diligence request
Trust/compliance	Public pages emphasize compliance, terms, or regulated workflows.	medium	Claims may outpace verified audits or regulatory history.	Request audit results and compliance incidents.
Product breadth	4 public product/service rows identified.	medium	Breadth can mask underused or low-margin products.	Request product-level usage and gross margin.
Distribution	4 public or inferred GTM channels identified.	low-to-medium	No channel mix or CAC data public.	Request sales funnel, CAC, and payback by channel.

Competitive market map Position the target and competitor types by public evidence.

Chapter 05

05Marketing, Sales, and Distribution

GTM appears partner/research-led and historically alliance-led, with sparse recent public commercial updates and no CAC, pipeline, or sales productivity evidence.

EC-010

V.A Strategy and implementation

partially verified confidence: medium

Public sources provide structured evidence for strategy and implementation, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section V.A.

Distribution channels and GTM motions
channel	target segment	public evidence	evidence claim id	verification status
Strategic investor ecosystem	China healthcare/data ecosystem	Tencent, VCANBIO, and UEC relationships are public	EC-003	partially_verified
Research and hospital collaborations	Clinical/translational partners	Services page references leading health research institutions/providers	EC-005	partially_verified
Company news / scientific reputation	Research visibility	Leadership and news pages highlight Jun Wang, highly cited researchers, and collaborations	EC-007	partially_verified
Diagnostic product channel	Clinical laboratories	ELISA kit page indicates trained clinical laboratory personnel and EUA context	EC-006	partially_verified

V.B Major Customers

partially verified confidence: medium

Public sources provide limited direct evidence for major customers; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section V.B.

V.C Principal avenues for generating new business

partially verified confidence: medium

Public sources provide structured evidence for principal avenues for generating new business, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section V.C.

Marketing signal summary
signal	observed public evidence	interpretation	diligence gap	evidence claim id
Owned website/product pages	Active pages describe Digital Life Platform, Biomarker discovery services, SARS-CoV-2 NP Ab ELISA kit.	Product-led messaging is visible.	Traffic, conversion, CAC, and pipeline attribution private.	EC-002
Public proof points	Historical alliances, leadership bios, and biomarker/ELISA claims.	Proof points support credibility but require validation.	Need time period, denominator, and independent corroboration.	EC-010
Sales productivity	No quota, sales cycle, pipeline, CAC, or sales headcount data public.	Cannot assess GTM efficiency.	Request sales productivity model.	EC-007

GTM channel mix evidence chart Chart public channel signals and undisclosed channel economics.

V.D Sales force productivity model

not publicly verifiable confidence: low

Public sources provide limited direct evidence for sales force productivity model; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section V.D.

V.E Ability to implement marketing plan with current and projected budgets

not publicly verifiable confidence: low

Public sources provide limited direct evidence for ability to implement marketing plan with current and projected budgets; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section V.E.

Chapter 06

06Research and Development

R&D is the core diligence topic: multi-omics data integration, biomarker discovery, diagnostic assays, and founder scientific reputation are visible, while datasets, studies, QA, and roadmap costs are private.

EC-011

VI.A Description of R&D organization

partially verified confidence: medium

Public sources provide structured evidence for description of r&d organization, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VI.A.

R&D personnel and technical leadership
name or role	function	public evidence	evidence claim id	verification status
Dr. Jun Wang	Founder and Chief Executive Officer	BGI co-founder; responsible for general management and business development; AI/bioinformatics background	EC-007	verified
Yingrui Li	Co-Founder and Chief Scientist	BGI background; more than one hundred papers; Forbes 30 under 30 Asia noted by company	EC-007	verified
Hao Li	Co-founder and CIO	Information systems and security background from BGI and China Netcom	EC-007	verified

Public R&D / technical org view Publicly visible leadership or technical roles; private org chart remains required.

VI.B New Product Pipeline

partially verified confidence: medium

Public sources provide structured evidence for new product pipeline, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VI.B.

Public product and research pipeline
project or capability	status	public evidence	evidence claim id	verification status
Biomarker discovery for cancer	Publicly marketed service area	Digital Life Platform used with LDCT and biomarker profiling; clinical validation private	EC-011	partially_verified
Chronic disorder precision medicine	Publicly marketed service area	Services page describes complications and rare diabetes subtype diagnosis use cases	EC-005	partially_verified
Infectious disease neutralizing antibody measurement	Publicly marketed service area	Services/product pages discuss COVID-19 antibodies and vaccine research support	EC-006	partially_verified
Meum / Digital Life Alliance	Historical platform ecosystem	Current activity and commercial status not public	EC-004	inconclusive

Chapter 07

07Management and Personnel

The company publishes concise biographies for three founders/leaders, but not a current org chart, headcount plan, compensation, incentive stock plans, or turnover.

EC-007

VII.A Organization Chart

partially verified confidence: medium

Public sources provide limited direct evidence for organization chart; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VII.A.

VII.B Historical and projected headcount by function and location

partially verified confidence: medium

Public sources provide structured evidence for historical and projected headcount by function and location, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VII.B.

Headcount and hiring signals
period	public signal	function or location	verification status	diligence request
2017 historical source	Wikipedia cites about 100 employees historically.	Shenzhen	partially_verified	Request current headcount by function, location, tenure, contractor status, and hiring plan.
2026 public-source review	Careers page active but total headcount and openings not disclosed in fetched content.	Multiple / not fully disclosed	partially_verified	Request recruiting funnel, open roles, attrition, and employee-relations records.

Headcount trend public anchors Plot public headcount anchors and undisclosed periods.

VII.C Senior management biographies

partially verified confidence: medium

Public sources provide structured evidence for senior management biographies, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VII.C.

Senior management roster
person or group	role	public bio or gap	evidence claim id	verification status
Dr. Jun Wang	Founder and Chief Executive Officer	BGI co-founder; responsible for general management and business development; AI/bioinformatics background	EC-007	verified
Yingrui Li	Co-Founder and Chief Scientist	BGI background; more than one hundred papers; Forbes 30 under 30 Asia noted by company	EC-007	verified
Hao Li	Co-founder and CIO	Information systems and security background from BGI and China Netcom	EC-007	verified

VII.D Compensation arrangements

not publicly verifiable confidence: low

Public sources provide limited direct evidence for compensation arrangements; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VII.D.

VII.E Incentive stock plans

not publicly verifiable confidence: low

Public sources provide limited direct evidence for incentive stock plans; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VII.E.

VII.F Significant employee relations problems, past or present

not publicly verifiable confidence: low

Public sources provide limited direct evidence for significant employee relations problems, past or present; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VII.F.

VII.G Personnel Turnover

not publicly verifiable confidence: low

Public sources provide structured evidence for personnel turnover, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VII.G.

Departures and turnover signals
signal	public evidence	verification status	risk interpretation	diligence request
Executive departures	No complete public departure schedule found.	not_publicly_verifiable	Cannot assess key-person retention or succession quality.	Provide two-year executive and employee turnover by function.
Employee-relations matters	No systematic public employee-relations record review completed.	not_publicly_verifiable	Potential hidden wage/hour, culture, or retention risks remain unresolved.	Provide HR claims, litigation, severance, benefits, and engagement survey summaries.

Chapter 08

08Legal and Related Matters

Legal/regulatory exposure centers on diagnostics, health/genomics data rights, clinical validation, China/cross-border privacy, IP ownership, and old partnership obligations.

EC-006

VIII.A Pending lawsuits against the Company

not publicly verifiable confidence: low

Public sources provide structured evidence for pending lawsuits against the company, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008 EC-009

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VIII.A.

Pending lawsuits against the company
matter	court or forum	public status	verification status	source or gap
Lawsuits against company	Not identified in reviewed public-source set	No material pending case found in reviewed public-source set	unverified	Chinese docket/regulatory searches and counsel letter required
Customer, employment, regulatory, or IP claims	Requires counsel/docket review	No comprehensive docket search performed	not_publicly_verifiable	Request litigation schedule, demand letters, settlements, and insurance notices.

VIII.B Pending lawsuits initiated by Company

not publicly verifiable confidence: low

Public sources provide structured evidence for pending lawsuits initiated by company, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008 EC-009

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VIII.B.

Pending lawsuits initiated by the company
matter	court or forum	public status	verification status	diligence request
Company-initiated litigation	Not identified in reviewed public-source set	No public company-initiated litigation identified in reviewed source set	unverified	Require IP enforcement and commercial-dispute schedule
IP enforcement / contract collections	Requires counsel confirmation	No schedule public	not_publicly_verifiable	Request initiated-claims schedule and recoverability assessment.

VIII.C Environmental and employee safety issues and liabilities

partially verified confidence: medium

Public sources provide limited direct evidence for environmental and employee safety issues and liabilities; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008 EC-009

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VIII.C.

VIII.D Material patents, copyrights, licenses, and trademarks

partially verified confidence: medium

Public sources provide structured evidence for material patents, copyrights, licenses, and trademarks, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008 EC-009

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VIII.D.

Material IP, regulatory, privacy, and contract issues
asset or matter	category	public evidence	evidence claim id	verification status	diligence request
iCarbonX brand and Digital Life Platform	Trade name / platform know-how	Company pages describe platform; trademark/patent registry search not completed	EC-005	partially_verified	Request ownership, assignments, licenses, registrations, and open-source/third-party dependency review.
SARS-CoV-2 NP Ab ELISA kit	Diagnostic product / regulatory file	Product page describes EUA context; current authorization and manufacturing file require review	EC-006	partially_verified	Request ownership, assignments, licenses, registrations, and open-source/third-party dependency review.
Biomarker algorithms and multi-omics datasets	Trade secrets / data assets	Core value likely depends on private datasets and algorithms not publicly auditable	EC-005	not_publicly_verifiable	Request ownership, assignments, licenses, registrations, and open-source/third-party dependency review.
Regulatory / diagnostics / data exposure	Regulatory / contracts	EUA diagnostic context, health/genomics data, cross-border privacy and clinical validation exposure	EC-006	partially_verified	Request NMPA/FDA status, IRB/ethics approvals, data consents, security audits, and adverse-event/regulatory correspondence

VIII.E Insurance coverage and material exposures

not publicly verifiable confidence: low

Public sources provide limited direct evidence for insurance coverage and material exposures; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008 EC-009

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VIII.E.

VIII.F Material contracts

not publicly verifiable confidence: low

Public sources provide limited direct evidence for material contracts; this section is primarily a diligence-request ledger.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008 EC-009

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Missing private records could conceal unfavorable economics, disputes, concentration, or compliance issues.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VIII.F.

VIII.G Regulatory agency problems

partially verified confidence: medium

Public sources provide structured evidence for regulatory agency problems, but private records remain required for complete diligence.

EC-001 EC-003 EC-010 EC-004 EC-005 EC-006 EC-007 EC-011 EC-008 EC-009

Evidence gaps

Private data-room records, management interviews, and third-party confirmations are required for complete diligence.

Hidden risks

Company-authored public evidence may overstate durability, scale, or differentiation without third-party validation.

Follow-up questions

Provide the private schedules and source documents responsive to checklist section VIII.G.

Legal and regulatory timeline Public legal/regulatory signals and private records needed.

Risk heatmap Map diligence risks by severity and likelihood.

Evidence

Evidence claims
ID	Claim	Status	Sources
EC-001	CB Insights lists iCarbonX as a private unicorn valued at $1B, with a 2016-04-12 unicorn date, Shenzhen location, healthcare industry classification, and named select investors Tencent and Vcanbio.	verified high	SRC-001
EC-002	iCarbonX says it was founded in 2015 by Jun Wang to create a future where people can drive health and defeat disease with advanced data and AI.	verified high	SRC-002 SRC-007
EC-003	Company-owned investor disclosures list Tencent, VCANBIO Life Sciences, and UEC Group as investors/partners supporting the company.	verified high	SRC-002
EC-004	iCarbonX company news lists a 2016 Series A financing, a 2017 Meum platform launch, Digital Life Alliance expansion, HealthTell partnership, HealthLoop investment, and research collaborations.	partially verified medium	SRC-003
EC-005	iCarbonX says its Digital Life Platform integrates genomics, proteomics, metabolomics, microbiome, and phenotypical profiling and shifted focus in 2019 toward innovative biomarker discoveries for translational work.	verified high	SRC-005
EC-006	iCarbonX publicly describes a SARS-CoV-2 NP Ab ELISA kit with 94.59% sensitivity, 95.24% specificity, laboratory-personnel intended use, reporting obligations, and FDA Emergency Use Authorization context.	partially verified medium	SRC-004
EC-007	iCarbonX leadership pages identify Dr. Jun Wang as Founder and CEO, Yingrui Li as Co-Founder and Chief Scientist, and Hao Li as Co-founder and CIO, with BGI and technical backgrounds.	verified high	SRC-006
EC-008	Wikipedia summarizes iCarbonX as a private Shenzhen company combining genomics with metabolites, bacteria, and lifestyle data to create a digitalized form of life, with historical investment and Digital Life Alliance activity.	partially verified medium	SRC-007
EC-009	Public sources do not disclose iCarbonX audited financial statements, current revenue, customer concentration, active product sales, cap table, debt, or cash runway.	not publicly verifiable high	SRC-001 SRC-002 SRC-003 SRC-005
EC-010	The most visible iCarbonX company-news items are concentrated in 2015-2018, with the copyright footer showing 2021 and company pages fetched with 2026 publish metadata; public evidence of recent commercial traction is thin.	partially verified medium	SRC-003 SRC-002 SRC-005
EC-011	iCarbonX Services page claims clinical/research use cases including 89%-91% accuracy for distinguishing malignant early lung nodules using integrative biomarkers with LDCT screening.	partially verified medium	SRC-005

Sources
ID	Publisher	Title	Accessed
SRC-001	CB Insights	The Complete List Of Unicorn Companies	2026-06-12
SRC-002	iCarbonX	Our Difference - iCarbonX	2026-06-12
SRC-003	iCarbonX	Company News - News - iCarbonX	2026-06-12
SRC-004	iCarbonX	Products - iCarbonX	2026-06-12
SRC-005	iCarbonX	Services - iCarbonX	2026-06-12
SRC-006	iCarbonX	Leadership - iCarbonX	2026-06-12
SRC-007	Wikipedia	ICarbonX	2026-06-12

Disclaimer

This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.